Semaglutide: Scientific Profile

Publicado el 12 de julio de 2026

Semaglutide (CAS 910463-68-2; NN9535) is a long-acting acylated analog of glucagon-like peptide-1 (GLP-1), widely used as a reference GLP-1 receptor agonist in metabolic research. It acts as a GLP-1 receptor agonist, enhancing glucose-dependent insulin secretion and modulating satiety. Research material.

Semaglutide is a synthetic peptide of 31 residues structurally derived from human glucagon-like peptide-1 (GLP-1), an endogenous incretin secreted by intestinal L cells. Identified by its development code NN9535 (synonym NNC 0113-0217) and registered with CAS number 910463-68-2, it has molecular formula C187H291N45O59 and a molecular weight of 4113.58 g/mol. It belongs to the class of GLP-1 receptor agonists (GLP-1RA) and has become one of the most widely used reference compounds in the research of incretin signaling, glycemic control and the regulation of energy balance.

From a structural point of view, Semaglutide retains the peptide backbone of the GLP-1(7-37) fragment with three key modifications that define its pharmacology. First, the alanine residue at position 8 (GLP-1 numbering) is replaced by alpha-aminoisobutyric acid (Aib), a non-proteinogenic amino acid that confers resistance to degradation by dipeptidyl peptidase-4 (DPP-4), the enzyme that rapidly inactivates native GLP-1. Second, the lysine at position 34 is replaced by arginine to selectively direct the acylation to the lysine residue at position 26. Third, on that lysine a side chain is incorporated composed of a spacer of two units of 2-(2-aminoethoxy)acetic acid (AEEA), a gamma-glutamate linker, and a C18 diacid fatty acid (stearic diacid). This lipid chain promotes a reversible, high-affinity binding to serum albumin, which reduces renal clearance and markedly prolongs the circulating half-life in research models, allowing prolonged exposure profiles compared with endogenous GLP-1.

The mechanism of action of Semaglutide centers on the activation of the GLP-1 receptor (GLP-1R), a class B G protein-coupled receptor expressed in pancreatic beta cells, the central nervous system, the gastrointestinal tract, and the cardiovascular system, among other tissues. Binding to the receptor activates the adenylate cyclase pathway, increasing intracellular levels of cyclic AMP and activating protein kinase A (PKA) and exchange factors such as Epac2. In beta-cell models, this signaling enhances insulin secretion in a strictly glucose-dependent manner, that is, the secretory response is amplified when blood glucose is elevated and decreases as glucose normalizes, a feature that in preclinical studies is associated with a low intrinsic risk of hypoglycemia. In parallel, Semaglutide suppresses glucagon secretion under conditions of hyperglycemia, slows gastric emptying, and acts on hypothalamic and brainstem nuclei involved in appetite regulation, contributing to the reduction in energy intake observed in animal models.

The documented research applications of Semaglutide are broad and reflect its role as a reference pharmacological tool within the incretin class. In models of type 2 diabetes and insulin resistance it is used to study the restoration of the insulin secretory response, peripheral glucose sensitivity, and pancreatic islet homeostasis. In models of obesity and feeding behavior it is used to investigate the central circuits of satiety, hypothalamic signaling, and the interaction between the gut-brain axis and energy balance. Additionally, there is a growing body of preclinical and clinical work exploring the effects of GLP-1 receptor agonists on cardiovascular parameters, low-grade inflammation, hepatic steatosis, and neuroprotection, fields in which Semaglutide figures as a representative compound. These uses correspond strictly to laboratory and research contexts.

With regard to the level of evidence, Semaglutide is distinguished from many experimental peptides by belonging to a pharmacological class with extensive support from human clinical trials: the class of GLP-1 receptor agonists, developed from the incretin biology characterized over the past decades. The molecule was developed through rational peptide engineering starting from native GLP-1, and the incretin class as a whole has a robust clinical database on glycemic control and body weight regulation. Nevertheless, within the catalog this material is offered exclusively as a research compound, and any reference to results must be understood within the framework of preclinical studies and the class literature, without constituting therapeutic guidance. Its combination of resistance to DPP-4, albumin binding, and potency at the GLP-1 receptor keeps it as one of the most useful tools for studying incretin signaling in the laboratory.